dc.contributor.author | Rondy, M | |
dc.contributor.author | Wiessing, L | |
dc.contributor.author | Hutchinson, S J | |
dc.contributor.author | Matheï, C | |
dc.contributor.author | Mathis, F | |
dc.contributor.author | Mravcik, V | |
dc.contributor.author | Norden, L | |
dc.contributor.author | Rosińska, M | |
dc.contributor.author | Scutelniciuc, O | |
dc.contributor.author | Suligoi, B | |
dc.contributor.author | Vallejo-Ruiz de Leon, Fernando | |
dc.contributor.author | Van Veen, M | |
dc.contributor.author | Kretzschmar, M | |
dc.date.accessioned | 2020-12-04T07:42:34Z | |
dc.date.available | 2020-12-04T07:42:34Z | |
dc.date.issued | 2013-03 | |
dc.identifier.citation | Epidemiol Infect. 2013 Mar;141(3):563-72. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11500 | |
dc.description.abstract | Monitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged. Predictors of HCV positivity were sought through a multilevel analysis using a mixed-effects logistic model, with study identifier as random intercept. HCV prevalence ranged from 21% to 86% across the studies. Overall, HCV prevalence was higher in IDUs recruited in drug treatment centres compared to those recruited in low-threshold settings (74% and 42%, respectively, P < 0·001). Recruitment setting remained significantly associated with HCV prevalence after adjustment for duration of injecting and recent injection (adjusted odds ratio 0·7, 95% confidence interval 0·6-0·8, P = 0·05). Recruitment setting may have an impact on HCV prevalence estimates of IDUs in Europe. Assessing the impact of mixed recruitment strategies, including respondent-driven sampling, on HCV prevalence estimates, would be valuable. | es_ES |
dc.description.sponsorship | This study contributes to the work of the ‘European Study Group for Mathematical Modelling and Epidemiological Analysis of Drug-Related Infectious Diseases, coordinated by EMCDDA and RIVM with funding from WHO/Europe and the government of The Netherlands. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cambridge University Press | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Needle-Exchange Programs | es_ES |
dc.subject.mesh | Patient Selection | es_ES |
dc.subject.mesh | Substance Abuse Treatment Centers | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Hepatitis C | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Prevalence | es_ES |
dc.subject.mesh | Research Design | es_ES |
dc.subject.mesh | Selection Bias | es_ES |
dc.subject.mesh | Seroepidemiologic Studies | es_ES |
dc.subject.mesh | Substance Abuse, Intravenous | es_ES |
dc.title | Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 22595549 | es_ES |
dc.format.volume | 141 | es_ES |
dc.format.number | 3 | es_ES |
dc.format.page | 563-72 | es_ES |
dc.identifier.doi | 10.1017/S0950268812000921 | es_ES |
dc.contributor.funder | World Health Organization (WHO/OMS) | es_ES |
dc.contributor.funder | Government of Netherlands | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1469-4409 | |
dc.relation.publisherversion | https://doi.org/10.1017/S0950268812000921 | es_ES |
dc.identifier.journal | Epidemiology and infection | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |